CoChat

Repurposing anti-inflammasome NRTIs for improving insulin sensitivity and reducing type 2 diabetes development

Open access

The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.

Abstract

Innate immune signaling through the NLRP3 inflammasome is activated by multiple diabetes-related stressors, but whether targeting the inflammasome is beneficial for diabetes is still unclear. Nucleoside reverse-transcriptase inhibitors (NRTI), drugs approved to treat HIV-1 and hepatitis B infections, also block inflammasome activation. Here, we show, by analyzing five health insurance databases, that the adjusted risk of incident diabetes is 33% lower in patients with NRTI exposure among 128,861 patients with HIV-1 or hepatitis B (adjusted hazard ratio for NRTI exposure, 0.673; 95% confidence interval, 0.638 to 0.710; P < 0.0001; 95% prediction interval, 0.618 to 0.734). Meanwhile, an NRTI, lamivudine, improves insulin sensitivity and reduces inflammasome activation in diabetic and insulin resistance-induced human cells, as well as in mice fed with high-fat chow; mechanistically, inflammasome-activating short interspersed nuclear element (SINE) transcripts are elevated, whereas SINE-catabolizing DICER1 is reduced, in diabetic cells and mice. These data suggest the possibility of repurposing an approved class of drugs for prevention of diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-18528-z

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Forest plot of incident diabetes. Hazard ratios based on a Cox proportional-hazards model and adjusted for the confounding variables listed in Supplementary Tables 5, 7, 9, 11, and 13 were estimated separately for each database. The dashed vertical line denotes a hazard ratio of 1.0, which represents no difference in risk between nucleoside reverse-transcriptase inhibitor (NRTI) exposure and non-exposure. The black horizontal bars represent 95% confidence intervals (CI) for unmatched models. The blue horizontal bars represent 95% CI for propensity score-matched models. P values derived from z tests for individual databases are reported. Inverse-variance-weighted random-effects and fixed-effect meta-analyses were performed to obtain a pooled estimate of the adjusted hazard ratio of incident diabetes for NRTI exposure (ever versus never). The prediction interval is reported. The estimate of heterogeneity (τ2) and the results of the statistical test of heterogeneity using the chi-square (χ2) test statistic and its degrees of freedom (df) are shown below the plot. The Higgins I2 statistic and its 95% CI are presented. The results of the statistical tests of overall effect, the z test statistics, and corresponding P values are presented. All tests were two-tailed.
Fig. 1 Forest plot of incident diabetes. Hazard ratios based on a Cox proportional-hazards model and adjusted for the confounding variables listed in Supplementary Tables 5, 7, 9, 11, and 13 were estimated separately for each database. The dashed vertical line denotes a hazard ratio of 1.0, which represents no difference in risk between nucleoside reverse-transcriptase inhibitor (NRTI) exposure and non-exposure. The black horizontal bars represent 95% confidence intervals (CI) for unmatched models. The blue horizontal bars represent 95% CI for propensity score-matched models. P values derived from z tests for individual databases are reported. Inverse-variance-weighted random-effects and fixed-effect meta-analyses were performed to obtain a pooled estimate of the adjusted hazard ratio of incident diabetes for NRTI exposure (ever versus never). The prediction interval is reported. The estimate of heterogeneity (τ2) and the results of the statistical test of heterogeneity using the chi-square (χ2) test statistic and its degrees of freedom (df) are shown below the plot. The Higgins I2 statistic and its 95% CI are presented. The results of the statistical tests of overall effect, the z test statistics, and corresponding P values are presented. All tests were two-tailed.CC BY · PubMed Central
Fig. 2 Bayesian meta-analysis of incident diabetes. Hazard ratios based on a Cox proportional-hazards model and adjusted for the confounding variables listed in Supplementary Tables 5, 7, 9, 11, and 13 were estimated separately for each database and are shown in black along with their 95% confidence intervals. A Bayesian meta-analysis was performed using a random-effects model and a weakly informative hierarchical half-Cauchy prior distribution85,86 for between-study variance with the assumption that it was unlikely for the between-study hazard ratios to vary by more than 3-fold (scale = 0.280). A sensitivity analysis to the choice of the prior by assuming that it was unlikely for the between-study hazard ratios to vary by more than 10-fold was also performed (scale = 0.587). The Bayesian shrinkage estimates and the summary estimates of the adjusted hazard ratio of incident diabetes for NRTI exposure (ever versus never), along with the 95% credible intervals, are shown in red (scale = 0.280) and blue (scale = 0.587). The dashed vertical line denotes a hazard ratio of 1.0, which represents no difference in risk between nucleoside reverse-transcriptase inhibitor (NRTI) exposure and non-exposure. The estimates of heterogeneity (τ2) and the posterior probabilities of a non-beneficial effect for each model are shown below the plot.
Fig. 2 Bayesian meta-analysis of incident diabetes. Hazard ratios based on a Cox proportional-hazards model and adjusted for the confounding variables listed in Supplementary Tables 5, 7, 9, 11, and 13 were estimated separately for each database and are shown in black along with their 95% confidence intervals. A Bayesian meta-analysis was performed using a random-effects model and a weakly informative hierarchical half-Cauchy prior distribution85,86 for between-study variance with the assumption that it was unlikely for the between-study hazard ratios to vary by more than 3-fold (scale = 0.280). A sensitivity analysis to the choice of the prior by assuming that it was unlikely for the between-study hazard ratios to vary by more than 10-fold was also performed (scale = 0.587). The Bayesian shrinkage estimates and the summary estimates of the adjusted hazard ratio of incident diabetes for NRTI exposure (ever versus never), along with the 95% credible intervals, are shown in red (scale = 0.280) and blue (scale = 0.587). The dashed vertical line denotes a hazard ratio of 1.0, which represents no difference in risk between nucleoside reverse-transcriptase inhibitor (NRTI) exposure and non-exposure. The estimates of heterogeneity (τ2) and the posterior probabilities of a non-beneficial effect for each model are shown below the plot.CC BY · PubMed Central
Fig. 3 Expression of DICER1 and Alu in human diabetic adipocytes and skeletal myocytes. The top panels show the results of western blotting of extracts of proteins from human adipocytes a and human myocytes b isolated from nondiabetic and diabetic persons. Immunoreactive bands corresponding to DICER1 and beta-actin (β-actin) are shown. The bottom panels show bar graphs of the densitometric analyses of the DICER1 western blots in the top panels that have been normalized to β-actin abundance and to the nondiabetic group data. *P = 0.04 (diabetic versus nondiabetic adipocytes), *P = 0.046 (diabetic versus nondiabetic myocytes), two-tailed unpaired Student t test. The top panels show the results of northern blotting of total RNA extracts from human adipocytes c and human myocytes d isolated from nondiabetic and diabetic persons. Hybridization bands corresponding to Alu RNA and 5.8S ribosomal RNA (5.8S rRNA) are shown. The bottom panels show bar graphs of the densitometric analyses of the Alu northern blots in the top panels that have been normalized to 5.8S rRNA abundance and to the nondiabetic group data. *P = 0.04 (diabetic versus nondiabetic adipocytes), *P = 0.03 (diabetic versus nondiabetic myocytes), two-tailed unpaired Student t test. Data are reported as mean ± s.e.m. n = 5 samples per group a–d. Source data are provided as a Source Data file.
Fig. 3 Expression of DICER1 and Alu in human diabetic adipocytes and skeletal myocytes. The top panels show the results of western blotting of extracts of proteins from human adipocytes a and human myocytes b isolated from nondiabetic and diabetic persons. Immunoreactive bands corresponding to DICER1 and beta-actin (β-actin) are shown. The bottom panels show bar graphs of the densitometric analyses of the DICER1 western blots in the top panels that have been normalized to β-actin abundance and to the nondiabetic group data. *P = 0.04 (diabetic versus nondiabetic adipocytes), *P = 0.046 (diabetic versus nondiabetic myocytes), two-tailed unpaired Student t test. The top panels show the results of northern blotting of total RNA extracts from human adipocytes c and human myocytes d isolated from nondiabetic and diabetic persons. Hybridization bands corresponding to Alu RNA and 5.8S ribosomal RNA (5.8S rRNA) are shown. The bottom panels show bar graphs of the densitometric analyses of the Alu northern blots in the top panels that have been normalized to 5.8S rRNA abundance and to the nondiabetic group data. *P = 0.04 (diabetic versus nondiabetic adipocytes), *P = 0.03 (diabetic versus nondiabetic myocytes), two-tailed unpaired Student t test. Data are reported as mean ± s.e.m. n = 5 samples per group a–d. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 4 Insulin-induced glucose uptake in human adipocytes and skeletal myocytes. The results of glucose uptake assays in human adipocytes a and in human skeletal myocytes b are shown. Cells from nondiabetic (Non-DM) persons were treated with either tumor necrosis factor (TNF; 2.5 nM) or with high glucose (25 mM) and high insulin (100 nM) (HG) to induce insulin resistance. Cells from diabetic (DM) and nondiabetic persons were treated with lamivudine (Lam; 100 μM) or phosphate-buffered saline (PBS; vehicle). Glucose uptake measurements were performed by exposing cells to insulin (20 nM) using a fluorescent derivative of glucose, and quantified as relative fluorescence units (RFU) and normalized to baseline (prior to insulin treatment) levels of fluorescence. Data are reported as mean ± s.e.m.* In Non-DM adipocytes, P = 0.02 (HG versus PBS), P = 0.01 (HG + 3TC versus HG), P = 0.01 (TNF versus PBS), P = 0.02 (TNF + 3TC versus TNF), two-tailed unpaired Student t test. In DM adipocytes, P = 0.02 (3TC versus PBS), two-tailed paired Student t test. n = 5 samples per group (a). In Non-DM myocytes, P < 0.001 (HG versus PBS), P = 0.001 (HG + 3TC versus HG), P < 0.001 (TNF versus PBS), P = 0.01 (TNF + 3TC versus TNF), two-tailed unpaired Student t test. In DM myocytes, P = 0.03 (3TC versus PBS), two-tailed paired Student t test. n = 6 (nondiabetic) or 5 (diabetic) samples per group (b). Source data are provided as a Source Data file.
Fig. 4 Insulin-induced glucose uptake in human adipocytes and skeletal myocytes. The results of glucose uptake assays in human adipocytes a and in human skeletal myocytes b are shown. Cells from nondiabetic (Non-DM) persons were treated with either tumor necrosis factor (TNF; 2.5 nM) or with high glucose (25 mM) and high insulin (100 nM) (HG) to induce insulin resistance. Cells from diabetic (DM) and nondiabetic persons were treated with lamivudine (Lam; 100 μM) or phosphate-buffered saline (PBS; vehicle). Glucose uptake measurements were performed by exposing cells to insulin (20 nM) using a fluorescent derivative of glucose, and quantified as relative fluorescence units (RFU) and normalized to baseline (prior to insulin treatment) levels of fluorescence. Data are reported as mean ± s.e.m.* In Non-DM adipocytes, P = 0.02 (HG versus PBS), P = 0.01 (HG + 3TC versus HG), P = 0.01 (TNF versus PBS), P = 0.02 (TNF + 3TC versus TNF), two-tailed unpaired Student t test. In DM adipocytes, P = 0.02 (3TC versus PBS), two-tailed paired Student t test. n = 5 samples per group (a). In Non-DM myocytes, P < 0.001 (HG versus PBS), P = 0.001 (HG + 3TC versus HG), P < 0.001 (TNF versus PBS), P = 0.01 (TNF + 3TC versus TNF), two-tailed unpaired Student t test. In DM myocytes, P = 0.03 (3TC versus PBS), two-tailed paired Student t test. n = 6 (nondiabetic) or 5 (diabetic) samples per group (b). Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 5 Expression of DICER1, B2, and insulin sensitivity in high-fat diet-fed mice. a The top three panels show the results of western blotting of extracts of proteins from subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and skeletal muscle tissue isolated from mice fed a normal diet (ND) or a high-fat diet (HFD). Immunoreactive bands corresponding to DICER1 and beta-actin (β-actin) are shown. The bottom three panels show bar graphs of the densitometric analyses of the DICER1 western blots in the top panels that have been normalized to β-actin abundance and to the ND group data. n = 10 (ND) or 9 (HFD) samples per group. *P = 0.01 (ND versus HFD in SAT), P < 0.001 (ND versus HFD in VAT), P = 0.01 (ND versus HFD in Skeletal muscle), two-tailed unpaired Student t test. b The top two panels show the results of northern blotting of total RNA extracts from visceral adipose tissue (VAT) and skeletal muscle tissue isolated from mice fed a normal diet (ND) or a high-fat diet (HFD). Hybridization bands corresponding to B2 RNA and 5.8S ribosomal RNA (5.8S rRNA) are shown. The bottom two panels show bar graphs of the densitometric analyses of the B2 northern blots in the top panels that have been normalized to 5.8S rRNA abundance and to the ND group data. n = 9 (ND) or 10 (HFD) samples per group. *P < 0.001 (ND versus HFD in VAT) and P = 0.001 (ND versus HFD in Skeletal muscle), two-tailed unpaired Student t test. Glucose tolerance test (GTT; c) and insulin tolerance test (ITT; d) measurements, and area under the curve (AUC) quantification in mice fed a normal diet, a high-fat diet and treated with phosphate-buffered saline vehicle (HFD + Vehicle), or a high-fat diet and treated with once-daily intraperitoneal administration of lamivudine (70 mg/kg of body weight) (HFD + Lam). Data are reported as mean ± s.e.m. n = 10 (ND), 8 (HFD + Vehicle), or 10 (HFD + Lam) samples per group c. n = 10 (ND), 8 (HFD + Vehicle), or 9 (HFD + Lam) samples per group d. *In GTT, P < 0.001 (HFD + Vehicle versus Normal Diet) and P = 0.002 (HFD + 3TC versus HFD + Vehicle), two-tailed unpaired Student t test. *In ITT, P < 0.001 (HFD + Vehicle versus Normal Diet) and P = 0.003 (HFD + 3TC versus HFD + Vehicle), two-tailed unpaired Student t test. Source data are provided as a Source Data file.
Fig. 5 Expression of DICER1, B2, and insulin sensitivity in high-fat diet-fed mice. a The top three panels show the results of western blotting of extracts of proteins from subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and skeletal muscle tissue isolated from mice fed a normal diet (ND) or a high-fat diet (HFD). Immunoreactive bands corresponding to DICER1 and beta-actin (β-actin) are shown. The bottom three panels show bar graphs of the densitometric analyses of the DICER1 western blots in the top panels that have been normalized to β-actin abundance and to the ND group data. n = 10 (ND) or 9 (HFD) samples per group. *P = 0.01 (ND versus HFD in SAT), P < 0.001 (ND versus HFD in VAT), P = 0.01 (ND versus HFD in Skeletal muscle), two-tailed unpaired Student t test. b The top two panels show the results of northern blotting of total RNA extracts from visceral adipose tissue (VAT) and skeletal muscle tissue isolated from mice fed a normal diet (ND) or a high-fat diet (HFD). Hybridization bands corresponding to B2 RNA and 5.8S ribosomal RNA (5.8S rRNA) are shown. The bottom two panels show bar graphs of the densitometric analyses of the B2 northern blots in the top panels that have been normalized to 5.8S rRNA abundance and to the ND group data. n = 9 (ND) or 10 (HFD) samples per group. *P < 0.001 (ND versus HFD in VAT) and P = 0.001 (ND versus HFD in Skeletal muscle), two-tailed unpaired Student t test. Glucose tolerance test (GTT; c) and insulin tolerance test (ITT; d) measurements, and area under the curve (AUC) quantification in mice fed a normal diet, a high-fat diet and treated with phosphate-buffered saline vehicle (HFD + Vehicle), or a high-fat diet and treated with once-daily intraperitoneal administration of lamivudine (70 mg/kg of body weight) (HFD + Lam). Data are reported as mean ± s.e.m. n = 10 (ND), 8 (HFD + Vehicle), or 10 (HFD + Lam) samples per group c. n = 10 (ND), 8 (HFD + Vehicle), or 9 (HFD + Lam) samples per group d. *In GTT, P < 0.001 (HFD + Vehicle versus Normal Diet) and P = 0.002 (HFD + 3TC versus HFD + Vehicle), two-tailed unpaired Student t test. *In ITT, P < 0.001 (HFD + Vehicle versus Normal Diet) and P = 0.003 (HFD + 3TC versus HFD + Vehicle), two-tailed unpaired Student t test. Source data are provided as a Source Data file.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 91 references

Cited by

See all 66

Metadata

Authors
Ambati, J., Magagnoli, J., Leung, H., Wang, S.-B., Andrews, C. A., Fu, D., Pandey, A., Sahu, S., Narendran, S., Hirahara, S., Fukuda, S., Sun, J., Pandya, L., Ambati, M., Pereira, F., Varshney, A., Cummings, T., Hardin, J. W., Edun, B., Bennett, C. L., Ambati, K., Fowler, B. J., Kerur, N., Röver, C., Leitinger, N., Werner, B. C., Stein, J. D., Sutton, S. S., & Gelfand, B. D.
Affiliations
  • University of Virginia Medical Center (US)
  • University of South Carolina (US)
  • University of Virginia (US)
  • University of Michigan (US)
  • University of Tsukuba (JP)
  • Baystate Medical Center (US)
  • University of Kentucky (US)
  • Universitätsmedizin Göttingen (DE)
Corresponding author
Ambati, Jayakrishna
Venue
Nature Communications
Published
2020-09-23
Volume
11
Issue
1
Pages
4737-4737
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3089058753
Cited by
66
References
91
Citations by year
2026: 9 · 2025: 16 · 2024: 14 · 2023: 11 · 2022: 3 · 2021: 13
FWCI
0.65
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (publishedVersion)
  • UKnowledge (University of Kentucky) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
  • Institutional Repositories DataBase (IRDB) (submittedVersion)
  • Terrestrial Environment Research Center (University of Tsukuba) (submittedVersion, cc-by)
Funders
U.S. Department of Health & Human Services | NIH | National Eye Institute (R01EY028027)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
nucleoside reverse transcriptase inhibitors, NLRP3 inflammasome, type 2 diabetes prevention, insulin sensitivity, drug repurposing, lamivudine, HIV-1, hepatitis B, DICER1, insulin resistance, high-fat diet, innate immune signaling
MeSH terms
Animals, Cell Survival, Diabetes Mellitus, Type 2, Hepatitis B, Humans, Insulin Resistance, Male, Mice, Inbred C57BL, HIV-1, Adipocytes, Reverse Transcriptase Inhibitors, Muscle Cells, Ribonuclease III, Mice, DEAD-box RNA Helicases, Drug Repositioning, Inflammasomes, Diet, High-Fat

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Repurposing anti-inflammasome NRTIs for improving insulin sensitivity and reducing type 2 diabetes development. https://app.cochat.ai/papers/10.1038/s41467-020-18528-z
The paper
Ambati, J., Magagnoli, J., Leung, H., Wang, S.-B., Andrews, C. A., Fu, D., Pandey, A., Sahu, S., Narendran, S., Hirahara, S., Fukuda, S., Sun, J., Pandya, L., Ambati, M., Pereira, F., Varshney, A., Cummings, T., Hardin, J. W., Edun, B., . . . Gelfand, B. D. (2020). Repurposing anti-inflammasome NRTIs for improving insulin sensitivity and reducing type 2 diabetes development. Nature Communications. https://doi.org/10.1038/s41467-020-18528-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.